Europe Molecular Diagnostics Market

The Europe molecular diagnostics market is estimated to grow from USD 6.05 billion in 2026 to USD 10.15 billion by 2031, at a CAGR of 10.9%. The increase in healthcare spending, which enhances access to advanced diagnostic care, is a key factor driving market growth. Additionally, the growing geriatric population and the rising prevalence of infectious diseases and cancer, both of which require sophisticated diagnostic tools, including molecular diagnostics for early disease control, are significant contributors to this growth. Furthermore, the demand for precise diagnostic tools in both public and private healthcare facilities is further accelerating the market expansion.

In April 2025, Cepheid (a subsidiary of Danaher Corporation, US) and Oxford Nanopore Technologies Plc (UK) announced a strategic collaboration to develop a joint research-use-only (RUO) workflow that integrates Cepheid’s GeneXpert system with Oxford Nanopore’s sequencing platform. The collaboration aims to enable rapid, in-house infectious disease analysis, delivering results within hours.

In January 2024, Illumina, Inc. (US) entered into an agreement with Janssen Research & Development, LLC, through Janssen Global Services, LLC (Belgium), for the development of Illumina’s novel molecular residual disease (MRD) assay. The agreement focuses on a whole-genome sequencing multi-cancer research solution designed to detect ctDNA and better understand disease persistence or recurrence following clinical intervention.

To know about the assumptions considered for the study download the pdf brochure

Companies such as QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Danaher (US), Hologic, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Revvity (US), and Abbott (US) have adopted various strategies to expand their offerings and increase their market shares. These strategies include collaborations, acquisitions, development of new products, and contractual agreements, among other approaches.

Danaher (US) is one of the most prominent players in the Europe molecular diagnostics market, driven by its strong focus on innovative diagnostic solutions and scalable laboratory systems tailored for high-throughput testing as well as decentralized settings. The company’s core strengths lie in automation, operational efficiency, and system reliability, which align well with the increasing testing volumes and evolving requirements of the region’s healthcare landscape.

Roche (Switzerland) is a leading player in the Europe molecular diagnostics market due to its strong and well-established molecular diagnostics portfolio and a long-standing presence across European healthcare systems. The company offers a broad range of molecular testing solutions covering infectious diseases, oncology, and companion diagnostics supported by reliable platforms & integrated workflows. Roche’s close alignment with clinical needs and focus on high-quality & standardized testing have enabled widespread adoption of its molecular diagnostics solutions.

Market Ranking

bioMérieux (France), Illumina (US), Danaher (US), QIAGEN (Netherlands), and Roche (Switzerland) are some of the prominent players in this market, primarily owing to their diverse diagnostic portfolios and continuous technological developments.

Roche maintains a strong position through its integrated MDx portfolio, combining testing platforms, automation, and companion diagnostics. Danaher is well established in PCR-based molecular diagnostics, supported by a broad range of assays and automated systems that generate consistent demand for consumables. Illumina plays a central role in next-generation sequencing, with its platforms commonly used for cancer profiling, genetic testing, and advanced molecular analysis. bioMérieux is recognized for its focus on infectious disease diagnostics, providing solutions used for rapid & specific pathogen detection. QIAGEN supports the molecular testing workflow through its capabilities in sample preparation, nucleic acid extraction, and PCR-based assays, enabling reliable, end-to-end molecular diagnostics.

Related Reports:

Europe Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com